Loading...
19 items
2026-07-24
Zeria Pharmaceutical Co., Ltd., ¥ 25.0, Cash Dividend, Sep-29-2026
2026-06-23
Zeria Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026
2026-06-09
Zeria Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the First six months and for the fiscal Year Ending March 31, 2027. For the First six months, it expects Net sales of JPY 45,000 million, Operating profit of JPY 6,000 million, Profit attributable to owners of parent of JPY 4,000 million and Basic earnings per share of JPY 90.75. For the full year, it expects Net sales of JPY 95,000 million, Operating profit of JPY 13,000 million, Profit attributable to owners of parent of JPY 10,000 million and Basic earnings per share of JPY 226.86.
2026-06-09
Zeria Pharmaceutical Co., Ltd. provided year end dividend guidance for the year ending March 31, 2027. For the year end, the company expects dividend of JPY 25.00 per share against previous paid dividend of JPY 25.00 per share a year ago.
2026-06-09
Zeria Pharmaceutical Co., Ltd. at its AGM to be held on June 26, 2026 proposed a dividend for the year ended March 31, 2026 of JPY 25.00 per share against dividend of JPY 24.00 per share a year ago. Payable on June 29, 2026. The company provided dividend guidance for the second quarter of the fiscal year ending March 31, 2027 of JPY 25.00 per share against paid dividend of JPY 24.00 per share a year ago.
2026-05-30
Zeria Pharmaceutical Co., Ltd. expected to report Q1 2027 results on July 30, 2026. This event was calculated by S&P Global (Created on May 30, 2026).
2026-05-08
Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
2026-05-08
Zeria Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 08, 2026
2026-05-08
Zeria Pharmaceutical Co., Ltd., Board Meeting, May 08, 2026. Agenda: To consider Dividends from Surplus; and to consider the candidates for Directors to be proposed at the 72nd Ordinary Stockholders' General Assembly scheduled to be held on June 26, 2026.
2026-04-09
Zeria Pharmaceutical Co., Ltd., Board Meeting, Apr 09, 2026. Agenda: To consider and approve Change in the Position of an Executive Officer (effective April 9, 2026).
2026-02-23
Zeria Pharmaceutical Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 64,077.2 million compared to JPY 64,773.4 million a year ago. Net income was JPY 5,554.16 million compared to JPY 8,226.7 million a year ago. Basic earnings per share from continuing operations was JPY 126 compared to JPY 186.63 a year ago.
2026-02-05
Zeria Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 7, 2026. This event was calculated by S&P Global (Created on February 5, 2026).
2026-02-05
Zeria Pharmaceutical Co., Ltd., Board Meeting, Feb 05, 2026. Agenda: To resolve to cancel company's treasury shares pursuant to Article 178 of the Companies Act of Japan.
2025-12-23
Zeria Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
2025-11-11
Zeria Pharmaceutical Co., Ltd. announced the dividend of JPY 24.00 per share for the second quarter of Year ending March 31, 2026, payable on December 1, 2025 against JPY 23.00 per share a year ago.
2025-11-06
Zeria Pharmaceutical Co., Ltd. revised consolidated financial guidance for the First Six Months of the Fiscal Year Ending March 31, 2026. For the six months, the company expected net sales of JPY 39,960 million, Operating profit of JPY 3,640 million, Profit attributable to owners of parent of JPY 1,730 million and Basic earnings per share of JPY 39.25 as compared to net sales of JPY 43,000 million, Operating profit of JPY 5,000 million, Profit attributable to owners of parent of JPY 4,000 million and Basic earnings per share of JPY 90.75. Reasons for the Revision: For the First Six Months of the Fiscal Year Ending March 31, 2026, both sales and profits will fall below the initial forecasts. This outlook is due to a corrective decline in overseas markets following a significant increase in shipments during the fourth quarter of the previous fiscal year, along with issues with production equipment at the factory contracted to manufacture Asacol, which resulted in insufficient product supply for a certain period. However, the affected production equipment has been restored, and the product supply system is already back to normal. The Company expects a recovery to levels in line with the initial forecasts for the full-year. Furthermore, due to the sharp appreciation of the Swiss franc against European currencies such as the euro and British pound, significant foreign exchange losses are anticipated. Consequently, the decline in ordinary profit and profit attributable to owners of parent are expected to be greater than that in operating profit.
2025-11-06
Zeria Pharmaceutical Co., Ltd., ¥ 24.0, Cash Dividend, Mar-30-2026
2025-11-05
Zeria Pharmaceutical Co., Ltd. expected to report Q3 2026 results on January 30, 2026. This event was calculated by S&P Global (Created on December 23, 2025).
2025-11-05
Zeria Pharmaceutical Co., Ltd., Board Meeting, Nov 05, 2025. Agenda: To consider Cancellation of Treasury Shares.
2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | 91,118 | 89,159 | 86,615 | 84,849 | 85,345 | 87,311 | 82,579 | 81,469 | 78,876 | 75,725 | 74,573 |
Pretax Income Excl.Unusual Items | 10,812 | 11,042 | 9,465 | 7,546 | 9,042 | 12,840 | 9,729 | 10,966 | 10,616 | 8,512 | 10,066 |
Total Assets | 174,685 | 179,697 | 166,225 | 158,736 | 151,219 | 159,171 | 156,580 | 158,339 | 152,115 | 150,533 | 153,067 |
Total Liabilities | 66,413 | 71,093 | 70,049 | 66,928 | 63,598 | 69,375 | 71,342 | 69,773 | 69,939 | 70,705 | 74,330 |
Cash & Cash Equivalents | 27,706 | 27,760 | 24,154 | 22,652 | 19,978 | 23,592 | 24,517 | 24,360 | 19,897 | 20,323 | 19,534 |
Total Common Equity | 108,039 | 108,396 | 96,014 | 91,670 | 87,436 | 89,539 | 85,059 | 88,267 | 81,931 | 79,622 | 78,469 |
Book Value Per Share (BVPS) | 2,451.01 | 2,459.11 | 2,178.21 | 2,079.65 | 1,983.6 | 2,031.31 | 1,929.67 | 2,002.45 | 1,858.7 | 1,806.31 | 1,780.15 |
Net Change in Cash | 4,167 | 360 | 4,863 | 3,826 | 2,510 | ||||||
Capital Expenditure | -2,361 | -1,968 | -1,429 | -2,238 | -2,900 |
Zeria Pharmaceutical revealed its financial results for the second quarter of 2026 on August 06, 2026, with revenues of 21.45B yen and net income of 866.2M yen, representing a revenue increase of 10.1%, along with a significant decline of approximately 20.6% in EPS compared to the same quarter last year.
In addition, the EBITDA margin improved from 17.49% in the corresponding quarter last year to 19.77%. and it trades at 10.3x times current year's earnings, which is lower than the sector average (P/E 10.9x).
